About: Viruses as key modulators of the TGF‐β pathway; a double‐edged sword involved in cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Viruses as key modulators of the TGF‐β pathway; a double‐edged sword involved in cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Viruses as key modulators of the TGF‐β pathway; a double‐edged sword involved in cancer
Creator	Faghihloo, \| Mirzaei, Habibollah
topic	covid:3120ea8763d50603309035c1d5843f15a6130de5#this
Source	Medline; PMC
abstract	Transforming growth factor‐β (TGF‐β) signaling pathway is a key network in cell signaling that controls vital processes such as proliferation, differentiation, apoptosis, epithelial‐mesenchymal transition, and migration, thus acting as a double‐edged sword in normal development and diseases, in particular organ fibrosis, vascular disorders, and cancer. Early in tumorigenesis, the pathway exerts anti‐tumor effects through suppressing cell cycle and inducing apoptosis, while during late stages, it functions as a tumor promoter by enhancing tumor invasiveness and metastasis. This signaling pathway can be perturbed by environmental and genetic factors such as microbial interference and mutation, respectively. In this way, the present review describes the modulation of the TGF‐β pathway by oncogenic human viral pathogens and other viruses. The main mechanisms by which viruses interferes with TGF‐β signaling seems to be through (1) the alteration of either TGF‐β protein expression or activation, (2) the modulation of the TGF‐β receptors or SMADs factors (by interfering with their levels and functions), (3) the alteration of none‐SMAD pathways, and (4) indirect interaction with the pathway by the modulation of transcriptional co‐activator/repressor and regulators of the pathway. Given the axial role of this pathway in tumorigenesis, it can be regarded as an attractive target for cancer therapy. Hence, further investigations on this subject may represent molecular targets among either TGF‐β signaling molecules or viral factors for the treatment and management of viral infection consequences such as cancer.
has issue date	2018-01-18(xsd:dateTime)
bibo:doi	10.1002/rmv.1967
bibo:pmid	29345394
has license	no-cc
sha1sum (hex)	3120ea8763d50603309035c1d5843f15a6130de5
schema:url	https://doi.org/10.1002/rmv.1967
resource representing a document's title	Viruses as key modulators of the TGF‐β pathway; a double‐edged sword involved in cancer
has PubMed Central identifier	PMC7169117
has PubMed identifier	29345394
schema:publication	Rev Med Virol
resource representing a document's body	covid:3120ea8763d50603309035c1d5843f15a6130de5#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/3120ea8763d50603309035c1d5843f15a6130de5
is schema:about of	named entity 'PROCESSES' named entity 'EFFECTS' named entity 'apoptosis' named entity 'SMADs' named entity 'SMAD' named entity 'HPV' named entity 'H1N1' named entity 'PI3' named entity 'Id1' named entity 'Adenovirus' named entity 'p21' named entity 'protein' named entity 'Egr-1' named entity 'SMAD5' named entity 'EBOV' named entity 'pathology' named entity 'malignant transformation' named entity 'PAI-1' named entity 'binding site' named entity 'PI3K-Akt' named entity 'TGF-β' named entity 'TGF-β' named entity 'CBP' named entity 'TGF-β' named entity 'TGF-β signaling pathway' named entity 'TGF-β signaling pathway' named entity 'TGF-β signaling' named entity 'integrin' named entity 'SMADs' named entity 'oncogenic' named entity 'GRP94' named entity 'TGF-β' named entity 'lytic' named entity 'TGF-β' named entity 'overexpresses' named entity 'TGF-β' named entity 'binding activity' named entity 'SMAD2/3' named entity 'THBS' named entity 'TGF-β' named entity 'murine' named entity 'infection' named entity 'CBP' named entity 'chronic liver disease' named entity 'SMAD4' named entity 'naive T cells' named entity 'Egr-1' named entity 'fibrogenic' named entity 'p300' named entity 'TGF-β' named entity 'HCV' named entity 'PPM1a' named entity 'cytokine' named entity 'TGF-β' named entity 'LOH' named entity 'HBV' named entity 'miR-146a' named entity 'NS3' named entity 'RNA virus' named entity 'SMADs' named entity 'HCC' named entity 'c-Jun N-terminal kinase' named entity 'p300' named entity 'SMAD3' named entity 'TGF-β' named entity 'ERK' named entity 'transcriptional activation' named entity 'ECM' named entity 'CMV' named entity 'SMADs' named entity 'TGF-β' named entity 'SMAD4' named entity 'B-cell' named entity 'HTLV-1' named entity 'TGF-β' named entity 'SMAD3' named entity 'head and neck cancers' named entity 'tumoral'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software